ArticleFrontiers in oncology2020

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience.

Pei-Ying Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.